HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial:: an extended virology study

被引:25
|
作者
Aboulker, JP [1 ]
Babiker, AG [1 ]
Brun-Vézinet, F [1 ]
Darbyshire, JH [1 ]
Flandre, P [1 ]
Gazzard, B [1 ]
Nunn, AJ [1 ]
Goodall, R [1 ]
Aber, V [1 ]
Bragman, K [1 ]
Breckenridge, AM [1 ]
Carbon, C [1 ]
Charreau, I [1 ]
Chene, G [1 ]
Collis, P [1 ]
Cooper, D [1 ]
Dormont, J [1 ]
Fiddian, P [1 ]
Flepp, M [1 ]
Goebel, FD [1 ]
Hooker, M [1 ]
Lange, J [1 ]
Lüthy, R [1 ]
Peto, TEA [1 ]
Reiss, P [1 ]
Seligmann, M [1 ]
Stone, AB [1 ]
Thomis, J [1 ]
Vella, S [1 ]
Walckenaer, G [1 ]
Warrell, D [1 ]
Weller, IVD [1 ]
Wilber, R [1 ]
Yeni, P [1 ]
Yeo, J [1 ]
Withnall, R [1 ]
Goudsmit, J [1 ]
Huraux, JM [1 ]
van der Noorda, J [1 ]
Weiss, R [1 ]
Boucher, C [1 ]
Schuurman, R [1 ]
Descamps, D [1 ]
Jeffries, D [1 ]
Tedder, R [1 ]
Weber, J [1 ]
Krzyanowski, C [1 ]
Weverling, G [1 ]
机构
[1] UCL, Sch Med, Mortimer Market Ctr, MRC,Clin Trials Unit, London WC1E 6AU, England
关键词
antiviral therapy; progression; HIV-1; RNA; viral load;
D O I
10.1097/00002030-199901140-00008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To assess changes in HIV RNA and their relationship to disease progression. Design and setting: Delta was a randomized double-blind trial comparing zidovudine (ZDV) monotherapy with ZDV plus didanosine (ddl) or ZDV plus zalcitabine (ddC). Participants had AIDS (with CD4 cell counts above 50 x 10(6)/l), AIDS-related complex, or were asymptomatic with CD4 cell counts below 350 x 10(6)/l. The trial included both ZDV-naive and ZDV-experienced participants. Participants: A total of 1280 participants in the Delta trial whose serum samples had been stored at -70 degrees C and who had a minimum of one sample taken before the start of treatment and at least one later sample. Methods: HIV-1 RNA quantification was performed using the nucleic acid sequence-based amplification HIV-1 RNA quantitative assay with a cut-off of 800 copies/ml. Results: Reductions in HIV RNA by treatment group were consistent with the clinical results; in ZDV-naive participants the maximum median fall occurred at 4 weeks for all three groups (ZDV, 0.54 log(10) copies/ml; ZDV-ddl, 1.38 log(10) copies/ml; ZDV-ddC, 1.31 log(10), copies/ml). On average the reductions were smaller in ZDV-experienced participants but the difference between the monotherapy and combination arms was very similar in ZDV-naive and experienced participants. Baseline HIV RNA levels, adjusted for CD4 cell counts were highly predictive of time to virological response (HIV RNA < 800 copies/ml); HIV RNA nadirs achieved were predictive of survival. Viral load rebound following response was independent of treatment group and previous ZDV therapy. Conclusions: Virological changes in response to treatment are of Value in assessing prognosis and the activity of new therapies; in particular, there is a strong association between the minimum HIV RNA achieved in the first 16 weeks and subsequent clinical response. CD4 cell counts are independently predictive of response. (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:57 / 65
页数:9
相关论文
共 50 条
  • [21] Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels
    Sorstedt, Erik
    Nilsson, Staffan
    Blaxhult, Anders
    Gisslen, Magnus
    Flamholc, Leo
    Sonnerborg, Anders
    Yilmaz, Aylin
    BMC INFECTIOUS DISEASES, 2016, 16
  • [22] Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission
    Kumwenda, Newton I.
    Hoover, Donald R.
    Mofenson, Lynne M.
    Thigpen, Michael C.
    Kafulafula, George
    Li, Qing
    Mipando, Linda
    Nkanaunena, Kondwani
    Mebrahtu, Tsedal
    Bulterys, Marc
    Fowler, Mary Glenn
    Taha, Taha E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (02): : 119 - 129
  • [23] QC-PCR FOR MONITORING OF HIV-1 VIRAL LOAD IN PLASMA IN RESPONSE TO ANTIRETROVIRAL TREATMENT
    PIATAK, M
    SAAG, MS
    YANG, LC
    KAPPES, JC
    LUK, KC
    EMINI, EA
    SHAW, GM
    LIFSON, JD
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 : S77 - S77
  • [24] Causes and characteristics of death among HIV-1 infected patients with immunovirologic response to antiretroviral treatment
    May, T
    Lewden, C
    Bonnet, E
    Heripret, L
    Bevilacqua, S
    Jougla, É
    Costagliola, D
    Morlat, P
    Salmon, D
    Chêne, G
    PRESSE MEDICALE, 2004, 33 (21): : 1487 - 1492
  • [25] Emergence of HIV-1 Drug Resistance During Antiretroviral Treatment
    Libin Rong
    Zhilan Feng
    Alan S. Perelson
    Bulletin of Mathematical Biology, 2007, 69 : 2027 - 2060
  • [26] Prospective Antiretroviral Treatment of Asymptomatic, HIV-1 Infected Controllers
    Hatano, Hiroyu
    Yukl, Steven A.
    Ferre, April L.
    Graf, Erin H.
    Somsouk, Ma
    Sinclair, Elizabeth
    Abdel-Mohsen, Mohamed
    Liegler, Teri
    Harvill, Kara
    Hoh, Rebecca
    Palmer, Sarah
    Bacchetti, Peter
    Hunt, Peter W.
    Martin, Jeffrey N.
    McCune, Joseph M.
    Tracy, Russell P.
    Busch, Michael P.
    O'Doherty, Una
    Shacklett, Barbara L.
    Wong, Joseph K.
    Deeks, Steven G.
    PLOS PATHOGENS, 2013, 9 (10)
  • [27] Issues regarding antiretroviral treatment for patients with HIV-1 infection
    Macher, AM
    Goosby, EP
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 278 (15): : 1234 - 1235
  • [28] Emergence of HIV-1 drug resistance during antiretroviral treatment
    Rong, Libin
    Feng, Zhilan
    Perelson, Alan S.
    BULLETIN OF MATHEMATICAL BIOLOGY, 2007, 69 (06) : 2027 - 2060
  • [29] Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial
    Baxter, J. D.
    Dunn, D.
    White, E.
    Sharma, S.
    Geretti, A. M.
    Kozal, M. J.
    Johnson, M. A.
    Jacoby, S.
    Llibre, J. M.
    Lundgren, J.
    HIV MEDICINE, 2015, 16 : 77 - 87
  • [30] Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy
    Gay, Cynthia L.
    Bosch, Ronald J.
    Ritz, Justin
    Hataye, Jason M.
    Aga, Evgenia
    Tressler, Randall L.
    Mason, Stephen W.
    Hwang, Carey K.
    Grasela, Dennis M.
    Ray, Neelanjana
    Cyktor, Josh C.
    Coffin, John M.
    Acosta, Edward P.
    Koup, Richard A.
    Mellors, John W.
    Eron, Joseph J.
    JOURNAL OF INFECTIOUS DISEASES, 2017, 215 (11): : 1725 - 1733